IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4768
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$9M
Timothy Warbington
Creative Medical Technology Holdings, Inc. focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 25 | 22 | 12 | 10 | - | - | -92.1% | -87.9% | 60.0% | -55349.3% | -54603.2% | -100.0% | 0.0% | 5.0x | $9M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) receives a "Avoid" rating with a composite score of 25.0/100. It ranks #4768 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CELZ.
View All RatingsROE proxy -92.1% (sector -1.9%)
GM 60% vs sector 44%, OM -55349% vs sector 3%
Capital turnover N/A
Rev growth -100%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) as Avoid with a composite score of 25.0/100 at a current price of $1.84. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 25.0/100 places it at rank #4768 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 60% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. with an Avoid rating, assigning a composite score of 25.0/100 and 1 out of 5 stars. Ranked #4768 of 7,333 stocks, CELZ falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. registers a weak quality score of just 22/100, indicating significant profitability challenges. The company reports a return on equity of -92.1% (sector avg: -1.9%), gross margins of 60.0% (sector avg: 44.1%), net margins of -54603.2% (sector avg: 1.0%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
CELZ registers a value score of just 12/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.19x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -100.0% vs. a sector average of 6.7% and a return on assets of -87.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is experiencing notably weak momentum with a score of just 10/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -100.0% year-over-year, while a beta of 1.02 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
CELZ's stability score of 30/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.02 and a debt-to-equity ratio of 5.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 56/100 for CELZ suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 5.00x), micro-cap liquidity risk. With a $9M market cap (micro-cap), CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4768 of 7,333 overall (35th percentile). Key comparisons include ROE of -92.1% trailing the -1.9% sector median and operating margins of -55349.3% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CELZ currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (10) would have the largest impact on the composite score.
ROE 4745% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 36% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 2205250% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081

Gainers Oncorus, Inc. (NASDAQ: ONCR) shares surged 258% to $0.2781. Evelo Biosciences, Inc. (NASDAQ: EVLO) shares jumped 216.2% to $0.2622 after the company won U.S. Patent for prebiotic compositions and methods of use thereof for modulation of the microbiome. Navidea Biopharmaceuticals, Inc. (NASDAQ: NAVB) gained 58% to $0.1296. Navidea Biopharmaceutical recently posted a narrower first-quarter loss. Virgin Galactic Holdings, Inc. (NYSE: SPCE) shares climbed 32.1% to $5.36 as the company announced the start of commercial spaceline operations. The company said its first commercial spaceflight, "Galactic 01," is set to fly between June 27 and June 30. Plutonian Acquisition Corp. (NASDAQ: PLTNR) shares surged 24.2% to $0.41 after jumping 32% on Thursday. Microbot Medical Inc. (NASDAQ: MBOT) rose 21.7% to $3.48. Microbot Medical announced multiple peer reviewed abstracts accepted by the Cardiovascular and Interventional Radiological Society of Europe. VCI Global Limited (NASDAQ: VCIG) gained 20.2% to $2.91 after it announced a partnership with Fusionex to provide Artificial Intelligence and Big Data Services to clients. iRobot Corporation (NASDAQ: IRBT) shares climbed 19.2% to $50.15 after UK's Competition and Markets Authority cleared its acquisition deal with Amazon. NeuBase Therapeutics, Inc. (NASDAQ: NBSE) gained 17% to $3.2295. NeuBase Therapeutics recently announced a 1-for-20 reverse stock split. Humanigen, Inc. (NASDAQ: HGEN) shares rose 16.2% to $0.1866. Humanigen recently presented promising new hematologic data from PREACH-M trial for chronic myelomonocytic leukemia treatment at the 2023 European Hematology Association Congress. INVO Bioscience, Inc. (NASDAQ: INVO) gained 15.4% to $0.1960. SmileDirectClub, Inc. (NASDAQ: SDC) climbed 15% to $0.4950. AppHarvest, Inc. (NASDAQ: APPH) gained 14.1% to $0.4599. OpGen, Inc. (NASDAQ: OPGN) shares climbed 13.9% to $0.6950. OpGen, last month, posted a wider-than-expected quarterly loss. Ault Disruptive Technologies Corporation (NYSE: ADRT) shares gained 13.8% to $12.40. Lordstown Motors Corp. (NASDAQ: RIDE) gained 13.3% to $4.7683.. Cohen ...
WHO recognition of “etaroleucel” (CELZ-101) builds on prior “olastrocel” (CELZ-201) milestone, reinforcing platform credibility and supporting multi-program executionPHOENIX, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a regenerative medicine company advancing disruptive cell-based therapies for high-unmet-need indications, today announced the achievement of its second International Nonproprietary Name (INN) m

Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. HighPeak Energy posted GAAP earnings of 66 cents per share, versus market estimates of 65 cents per share. The company’s quarterly sales came in at $301.153 million versus expectations of $339.525 million. HighPeak Energy shares declined 15.3% to $13.49 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares jumped 404% to $11.65 after the company announced the launch of Lytus Cloud. CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) gained 167% to $6.81. CERo Therapeutics announced the publication in clinical cancer research a paper titled "Therapeutic Targeting of TIM-4-L With Engineered T CellsFor Acute Myeloid Leukemia." Brera Holdings PLC (NASDAQ: BREA) shares climbed 97.5% to $2.0150 after the company announced that its Executive Chairman, Daniel McClory, acquired a majority stake in the company. Grom Social Enterprises, Inc. (NASDAQ: GROM) gained 88.3% to $1.45. The company announced that it entered into a non-binding letter of intent to acquire Arctic7. Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 43% to $6.83. Creative Medical Technology announces FDA authorization for groundbreaking Type 1 diabetes prevention therapy under expanded access. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) gained 40.5% to $8.35 after the company received FDA Breakthrough Therapy Designation for its MM120 program in generalized anxiety disorder. The company also announced 12-week durability data from its Phase 2B study of MM120. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) jumped 34.2% to $2.1601 after the company announced that its subsidiary BioStrand developed a Foundation AI Model that uses Large Language Models Stacking and HYFT Technology. Beneficient (NASDAQ: BENF) shares rose 28.7% to $0.1287. Beneficient agreed to the financing of liquidity transactions for three separate funds managed by ff Venture Capital. MoneyLion Inc. (NYSE: ML) gained 28.3% to $67.43 ...

Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800 series. Workhorse Group Inc. (NASDAQ: WKHS) shares rose 19.5% to $0.7590 in pre-market trading after the company announced it has received IRS approval as a qualified manufacturer for the Commercial Clean Vehicle Credit. Super League Enterprise, Inc. (NASDAQ: SLE) shares gained 16.9% to $2.28 in pre-market trading after falling 40% on Tuesday. Bit Brother Limited (NASDAQ: BETS) shares rose 16.8% to $0.6896 in pre-market trading. In Dec. 2022, Bit Brother, through its subsidiary in New York, Bit Brother New York Inc, entered into a "Hedged Electricity Price" power supply agreement with a retail electricity provider (REP) within the jurisdiction of the Electric Reliability Council of Texas (ERCOT) for a term of 5 years. Mainz Biomed N.V. (NASDAQ: MYNZ) rose 16.6% to $4.27 in pre-market trading. Mainz Biomed's ColoFuture ...

Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares surged 64.6% to $2.19 in pre-market trading. Adamis Pharmaceuticals shares declined around 67% on Wednesday after the company reported pricing of $8 million public offering of 5.93 million units at a price of $1.35 per unit. T2 Biosystems, Inc. (NASDAQ: TTOO) rose 34.2% to $0.3261 in pre-market trading after gaining 54% on Wednesday. T2 Biosystems recently announced it received an extension to comply with the Nasdaq listing requirements. Fangdd Network Group Ltd. (NASDAQ: DUO) gained 23.2% to $0.2267 in pre-market trading after gaining over 13% on Wednesday. FangDD is scheduled to hold an extraordinary general meeting of shareholders on Sept. 15, 2023. Upwork Inc. (NASDAQ: UPWK) shares rose 17.1% to $11.67 in pre-market trading after the company posted upbeat second-quarter results and raised full-year guidance. EVgo, Inc. (NASDAQ: EVGO) shares gained 15.3% to $4.89 in pre-market trading after the company reported better-than-expected second-quarter results and announced leadership succession plan. Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares climbed 14.9% to $0.54 in pre-market trading after jumping ...